Insulin Market Competition: Payers Watching FDA 'Transition' Policy
Executive Summary
FDA policies around the upcoming regulatory reclassification of insulins as biologics may impact payers' ability to leverage competition and pricing in the market, Express Scripts suggests.
You may also be interested in...
Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.
Biologics Transition Plan From US FDA Will Consider Therapeutic Equivalence Ratings
While industry awaits formal guidance ahead of March 2020 transition deadline for certain protein products, FDA's Christl says plan will take into account therapeutic equivalence ratings when deciding whether products are 'deemed' licensed as full biologic applications or biosimilars.
Sanofi's Admelog, a Humalog Follow-On, Approved In US As 'Black Hole' For Insulins Looms
Short-acting insulin approved under 505(b)(2) pathway appears poised to receive three years of Hatch-Waxman exclusivity but would lose nine months of this protection under FDA's current interpretation of the 'transition provisions' for certain protein products that take effect in March 2020.